功能性消化不良根除幽门螺杆菌后症状改善相关因素分析

目的 探讨将治疗前胃黏膜组织学特征作为幽门螺杆菌（Hp）阳性功能性消化不良（FD）患者根除Hp后症状改善疗效预测指标的可能性,以提高消化不良患者的治疗水平.方法 连续调查240例进行胃镜检查Hp阳性FD患者,其中190例接受三联抗Hp治疗,另50例作为对照,给予奥美拉唑治疗,疗程均为7 d.治疗前胃黏膜组织学按新悉尼系统标准进行评估.治疗后1个月（治疗组和对照组）和6个月（治疗组）用C13-尿素呼气试验评估Hp.治疗前、治疗后1个月和6个月用消化不良调查表对症状程度进行评分,并计算仍有症状率,分析治疗前胃黏膜组织学与根除Hp后症状改善之间的相关性.结果 Hp阳性FD患者分别有35.3%和42.6%在根除Hp后1个月和6个月消化不良症状改善显效,且根除Hp者症状缓解率显著高于Hp根除失败者（P＜0.01）;也高于对照组（P＜0.01）.治疗前胃黏膜组织学指标中,炎症、活动性程度和Hp密度在根除Hp后症状改善显效的FD患者均显著高于有效和无效者（P＜0.05）.多元回归分析支持上述组织学因素与根除Hp后症状显著改善相关.结论 Hp阳性FD患者根除Hp后确实有部分患者症状显著改善.Hp阳性FD患者根除治疗前胃黏膜炎症、活动性程度和Hp密度能够预示根除Hp后症状改善的疗效.

Analysis of the factors related with symptomatic improvement after Helicobacter pylori eradication in functional dyspepsia patients

Objective To improve the management of dyspepsia by evaluating the potential role of pretreatment gastric histology as predictive factors on the symptomatic response after Helicobacter pylori (H. pylori) eradication in patients with functional dyspepsia (FD).Methods 240 FD patients with H. pylori infection out of 920 consecutive patients receiving gastroendoscopy due to dyspepsia were investigated, including 190 patients enrolled as the therapy group and administered with anti-H. pylori triple therapy. In addition, 50 patients were enrolled as the control group, in which omeprazole was an alternative to the triple therapy. The course of therapy in both groups was 7 days. Pretreatment gastric histology was evaluated by the updated Sydney system. C~ 13 urea breath test was performed to evaluate the H. pylori eradication results one month (both therapy group and control group) and six months (therapy group) after therapy. For each patient, the baseline, month 1 and month 6 symptom scores were assessed by a questionnaire of dyspepsia, including 12 symptom items of dyspepsia with scoring of severity. The relationship between pretreatment gastric histology and good symptom responses after H. pylori eradication was then analyzed.Results Of 35.3% and 42.6% patients with successful H. pylori eradication in the therapy group had a good symptomatic response one month and six months after the triple therapy respectively, higher than those from the patients who failed H. pylori eradication (month 1:35.3% vs 12.2%, P<0.01; month 6:42.6% vs 13.3%, P<0.01) and those from the control group (month 1:35.3% vs 13.6%, P<0.01). Among the pretreatment gastric histologic indicators, the severity of inflammation and activity and the density of H. pylori were higher in patients with good symptom response than in patients with moderate or poor symptom response (P<0.05), and the multivariate regression analysis confirmed the correlation.Conclusion Actually a certain subset (about 1/3) of FD patients with H. pylori infection do have dyspeptic symptom improvement after H. pylori eradication. The pretreatment severity of inflammation and activity and the density of H. pylori in gastric mucosa of FD patients with H. pylori infection are helpful in predicting the symptomatic response after H. pylori eradication.